Taf + Emtricitabine + Elvitegravir + Cobicistat Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: Elvitegravir – 150 mg + Cobicistat – 150 mg + Emtricitabine – 200 mg + TAF – 10 mg
Reference Brands: Genvoya(US & EU)
Category:
Anti Viral
Genvoya is a once-daily HIV-1 treatment combining TAF, Emtricitabine, Elvitegravir, and Cobicistat. It provides strong viral suppression with better kidney and bone safety than older TDF-based options. FDA and EMA approved.
TAF + Emtricitabine + Elvitegravir + Cobicistat is available in Tablet
and strengths such as Elvitegravir – 150 mg + Cobicistat – 150 mg + Emtricitabine – 200 mg + TAF – 10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, TAF + Emtricitabine + Elvitegravir + Cobicistat is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
TAF + Emtricitabine + Elvitegravir + Cobicistat can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Genvoya is a once-daily, fixed-dose combination of Tenofovir Alafenamide (TAF) 10 mg, Emtricitabine 200 mg, Elvitegravir 150 mg, and Cobicistat 150 mg, used for the treatment of HIV-1 infection. Approved by the US FDA and EMA, Genvoya offers potent viral suppression with improved renal and bone safety compared to older TDF-based regimens like Stribild. It is indicated for treatment-naïve adults and adolescents (≥12 years, ≥35 kg) with no resistance to its components. The inclusion of Cobicistat enhances Elvitegravir and TAF levels, enabling effective once-daily dosing. Genvoya simplifies HIV therapy and improves adherence through its single-tablet formulation.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing